MAPT and Cognitive impairment: In this sense, the present study is focused on the evaluation of the concordance between the results of CSF biomarkers levels (Aβ1-42, T-tau, and P-tau) and amyloid PET in the diagnosis of patients with cognitive impairment to provide additional tools, such as neuropsychological tests, in order to help in discrepant case diagnosis in clinical practice.